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Abstract
Maurocalcine is a scorpion venom toxin of 33 amino acid residues that bears a striking resemblance to the domain A. This domain
belongs to the II-III loop of Ca 1.1 which is implicated in excitation-contraction coupling. Besides the structural homology,v
maurocalcine also modulates RyR1 channel activity in a manner akin to a synthetic peptide of domain A. Owing to these similarities,
we hypothesized that maurocalcine and domain A may bind onto an identical region(s) of RyR1. Using a set of RyR1 fragments, we
demonstrate that peptide A and maurocalcine bind onto two discrete RyR1 regions: fragments 3 and 7 encompassing amino acid
residues 1021-1631 and 3201-3661, respectively. The binding onto fragment 7 is of greater importance and was thus further
investigated. We found that the amino acid region 3350-3501 of RyR1 (fragment 7.2) is sufficient for these interactions. Proof that
peptide A and maurocalcine bind onto the same site is provided by competition experiments in which binding of fragment 7.2 to
peptide A is inhibited by preincubation with maurocalcine. At the functional level, deletion of fragment 7 abolishes the maurocalcine
induced stimulation of H -ryanodine binding onto microsomes of COS-7 cells transfected with RyR1 without affecting the caffeine[3 ]
response.
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INTRODUCTION
In skeletal muscle cells, the activation of the plasma membrane dihydropyridine receptor induces, through the ryanodine receptor
(RyR1), a massive release of the calcium stored in the terminal cisternae of the sarcoplasmic reticulum (SR). The set of events, that starts
with the depolarization of the plasma membrane, sensed by the DHPR, and ends with the opening of the RyR1, is called
excitation-contraction (EC) coupling. Several results have led to the conclusion that the skeletal muscle EC coupling is based on a
mechanical process that is made possible by the physical interactions of the two Ca  channels ( ). The transmission of information from2+ 1
the DHPR to the RyR1 has been termed orthograde signal. In addition, the same physical interactions, which occur between RyR1 and
DHPR, have also been proposed to be responsible for a retrograde signal in which the DHPR calcium channel activity is controlled by
RyR1 ( , ). The identification of protein domains involved in these interactions between both DHPR and RyR1 and of proteins regulating2 3
these interactions remains today an important field of research.
The DHPR is composed of four different subunits , ,  and  ( ). The  subunit has been shown not only to form the pore regionα1 β α2δ γ 4 α1
and to carry the voltage sensitivity of the channel but also to be directly involved in the functional coupling of the DHPR with RyR1 ( ).5
Indeed, the cytoplasmic loop that links the domains II and III of the  subunit has been proposed to be responsible for the mechanicalα1
coupling between the DHPR and the RyR1 ( ). Within this cytoplasmic loop, two regions (domains A and C, respectively) have been6
shown to regulate ryanodine binding and channel gating of RyR1  ( ). Other regions of the  subunit have been found to interactin vitro 7 α1
with RyR1 but the functional role of these interactions is less essential or remains to be established ( ).8
Ryanodine receptors are formed by the homotetramer assembly of a 560 kDa polypeptide. RyR1 activity is regulated  by ain vitro
number of chemical compounds such as ATP, Ca , Mg , and proteins such as calmodulin and FK506 binding protein (FKBP12) ( ).2+ 2+ 9
Nevertheless, due to i) the extremely large size of RyR1, ii) the small number of high affinity effectors and iii) the absence of atomic
resolution structure, the mapping of the functional sites of RyR1 is still far from completion. Expression in dyspedic cells (lack RyR1) of
chimeric RyR1 channels, that carry sequences of different RyR isoforms, allowed the identification of domains engaged in the EC
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coupling process ( ). At the same time, binding sites for different effectors and partner proteins have been identified. As part of the10–12
search for molecules able to strongly modify RyR1 properties, toxins isolated from scorpion venoms have been described as being able to
induce important modifications in RyR1 channel behavior. Nowadays, these toxins represent the most effective effectors of RyR1. Among
them, imperatoxin A (IpTx A) and maurocalcine (MCa) have been extensively characterized both in terms of their effects on RyR1 and
their three-dimensional structure ( ). Interestingly, these two peptide toxins present some amino acid sequence homology with the13–18
domain A of DHPR  subunit and structural studies strongly suggest that the beta-sheet structure of these toxins could mimic that of theα1
domain A of the DHPR  subunit ( , ). In a previous work, we demonstrated that nanomolar concentrations of MCa induces a dramaticα1 16 17
conformational change of RyR1, witnessed by the increase in H -ryanodine binding (7-fold) and the induction of long-lasting channel[3 ]
openings ( , ). The observed homologies in amino acid sequences and in 3-D solution structure have prompted different authors to13 14
make the hypothesis that IpTx A and MCa could share a common binding site with the domain A of the DHPR  subunit on the RyR1.α1
We have therefore undertaken the identification of the amino acid region of RyR1 that carries the binding site for MCa and/or the domain
A of the skeletal DHPR  subunit.α1
In this work, a set of polypetides, covering the entire sequence of RyR1, was expressed  and tested individually for their abilityin vitro
to interact with either MCa or peptide A  (a synthetic peptide corresponding to the domain A of the skeletal DHPR  subunit). Wesk α1
identified a single domain of RyR1 interacting with both MCa and peptide A . We also showed that MCa and peptide A  compete for thesk sk
interaction on this domain. In order to asses the functional relevance of this domain for the effect of MCa on RyR1, we expressed a RyR1
channel that lacks the MCa binding domain in COS-7 cells and measured the effect of this deletion on the activation of ryanodine binding




The skeletal heavy SR vesicles were prepared from rabbit leg and back muscles by differential centrifugation, as previously described
( ). Vesicles were then solubilized in the presence of CHAPS, and RyR1 was purified by centrifugation of the solubilized proteins on a19
sucrose density gradient ( ) and stored in liquid nitrogen.20
Peptide syntheses
Peptides used in this work were synthesized as previously described ( , ), with the addition of an exogenous biotin on the14 21
C-terminal amino acid of i) MCa synthetic peptide, ii) peptide A , corresponding to residues Thr -Lys  of the DHPR 1s subunit, andsk 671 690 α
iii) peptide C , corresponding to the residues Glu -Pro  of the DHPR 1s subunit.sk 724 760 α
Pull-down experiments
Polystyrene magnetic beads (500 g) coated with streptavidine (Dynal) were incubated for 30 min at room temperature in the presenceμ
of biotinylated peptide (100 g/ml in buffer A; 150 mM NaCl, 2 mM EGTA, 2 mM CaCl , pCa5 and 20 mM HEPES, pH 7.4). Beads wereμ 2
then washed three times with buffer A and incubated for 2 h at room temperature with purified RyR1 (100 nM in buffer A). After washing
twice with buffer A, proteins bound to the immobilized peptide were eluted by boiling the beads for 5 min in 2.5  SDS and analyzed by%
Western blot using antibodies directed against RyR1 after separation on 8  SDS-PAGE.%
Cloning and expression of RyR1 fragments
RyR1 fragments F1-F8 were cloned in pSG5 vector (Stratagene) by a PCR-based method using specific primers with a linker for
further enzymatic digestion and insertion into the plasmid backbone ( ). Fragment F1 (from aminoacid 1 to 526) was cloned in RI22 Eco
and I restriction sites; F2 (aminoacids 527-1021) in HI- I sites; F3 (aminoacids 1022-1631), F4 (aminoacids 1632-2169), F5Not Bam Not
(aminoacids 2170-2697), F6 (aminoacids 2698-3200) and F7 (aminoacids 3201-3661) were cloned between RI and HI restrictionEco Bam
sites; F8 (aminoacids 3662-4244) was cloned between HI and I. Fragment F9 (aminoacids 4007-5038) was produced by cuttingBam Not
the original pCIneo-RyR1 plasmid (kindly provided by Dr. Allen) with I, followed by self-ligation.Xho
S-labeled RyR1 fragments were expressed using a coupled  transcription and translation system (TNT  kit, Promega),35 in vitro ™
according to the manufacturer s instructions. For pull-down assays, 5 l of the translation product were incubated with polystyrene’ μ
magnetic-beads coated with the peptide of interest as described above. After overnight incubation at 4 C, beads were washed with 1°
volume of buffer A. The associated proteins were eluted in denaturing buffer and analyzed by autoradiography after separation on
SDS-PAGE.
Expression of His-tagged RyR1 fragments in bacteria
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RyR1-F7 fragment was sub-cloned into three shorter segments (F7.1, F7.2 and F7.3) by a PCR-based approach. Briefly, the cDNA
was amplified using primers containing a linker encompassing a I site (in the 5  end of the forward primer) and a I (in the 3  end ofNco ′ Xba ′
the reverse primer). The PCR product was cloned using the I and I sites in the pMR78 plasmid that possesses a His-tag sequenceNco Xba
upstream of the polylinker ( ). E. Coli. BL21 pLys(DE3) bacteria were transformed with RyR1-F7( ) containing plasmid. Protein23 1–3
synthesis was induced by the addition of 1 mM IPTG (Sigma) to the culture media. 3 h after induction, the bacteria were collected by
centrifugation (3,000  for 10 min at 4 C) and suspended in MCAC buffer (20 mM Tris/HCl, 500 mM NaCl, 10  v/v glycerol, pH 8.0)g ° %
supplemented with protease inhibitors (Complete , Boehringer Mannheim). Cell lysis was induced by adding Triton X-100 (0.1  v/v),™ %
DNAse I (50 g) and MgCl  (10 mM). After 10 min incubation at room temperature, insoluble material was removed by centrifugation (15μ 2
min at 20,000  and 4 C). Solubilized proteins were then passed through a column of Ni-NTA agarose beads (Qiagen) equilibrated withg °
MCAC buffer. After wash with four volumes of MCAC buffer containing 60 mM imidazole, his-tagged RyR fragments were eluted in 0.5
ml fractions with MCAC buffer containing 250 mM imidazole and detected by Western blot analysis with antibodies directed against the
histidine tag (Sigma) used at a dilution factor of 1/10,000.
Transfection of COS-7 cells with RyR1 constructs and cytoimmunofluorescence
Wild-type RyR1 (RyR1wt) construct was cloned into a modified pCI-neo (Promega). Briefly, Nde  (nt 387) and Nhe  (nt 1085) sitesI I
on the pCI-neo vector were destroyed. Within the RyR1 cDNA, EcoR  (nt 9726) and Nhe  (nt 10014) sites were introduced and used forV I
cloning into the modified pCI-neo vector, for further expression studies in mammalian cells. RyR1?F7 construct was generated from the
pCI-neo/RyR1 clone (containing unique EcoR , Nhe  and Nde  restriction sites), by cutting out the sequence between nucleotides 9730V I I
and 10983.
COS-7 cells were transfected with the RyR1wt or RyR1 F7 containing plasmid using the linear polyethylenimine jetPEI  reagentΔ ™
according to the manufacturer s instructions (Qbiogene). Expression of RyR1wt and RyR1 F7 was controlled by immunofluorescence’ Δ
using antibodies directed against the C-terminal domain of RyR1 ( ). 48 h after transfection, cells were fixed in 4  paraformaldehyde for19 %
10 min, washed 3 times with PBS and permeabilized with 0.1  Triton X-100. Cells were then incubated for 1 h at room temperature in the%
presence of 1  BSA and 1  goat serum before adding anti-RyR1  antibodies (dilution 1:200 in PBS-0.1  Tween 20, PBS-T). After 2% % Cter %
h, the cells were washed four times with PBS-T and incubated for 30 min at room temperature with Alexa488-conjugated anti-rabbit IgG
(dilution 1:800 in PBS-T). Cells were then washed four times with PBS-T and mounted. Samples were analyzed by confocal laser
scanning microscopy, using a Leica TCS-SP2 operating system. Alexa , and DsRed fluorescence were excited and collected sequentially488
(400 Hz line by line) by using the 488 nm line of an argon laser for Alexa , and the 543 nm line of an helium-neon laser for DsRed488
excitation. Fluorescence emission was collected from 598 to 541 nm for Alexa , and from 554 to 625 nm for DsRed.488
Microsomes preparation
COS-7 cells were harvested in ice cold buffer containing 320 mM sucrose, 5 mM Hepes pH 7.4 and protease inhibitors, using a
cell-scraper. Cells were then homogenized using a Teflon potter and centrifuged for 5 min at 7,000  at 4 C. Microsomes were theng °
collected by centrifugation at 100,000  for 1 h at 4 C and resuspended in the same buffer. After quantification of protein concentration byg °
Bradford assay, samples were stored in liquid nitrogen.
[3H -ryanodine binding assay]
Microsomes preparation (100 g of proteins) obtained from control non-transfected COS-7 cells, and RyR1 or RyR1?F7-expressingμ
cells were incubated at room temperature for 1 h in presence of 1 M recombinant FKBP12 in a buffer containing 150 mM NaCl, 2 mMμ
EGTA and 2 mM CaCl  (pCa 5), 20 mM Hepes, pH 7.4. Microsomes were then incubated for 150 min at 37 C in the presence of H2 ° [3 ]
-ryanodine (10 nM) and caffeine (0 or 6 mM) or MCa (0 or 30 nM). Free and bound H -ryanodine were separated by filtration of the[3 ]
microsomes on Whatmann GF/B filters and H -ryanodine measured by liquid scintillation. Non-specific H -ryanodine binding was[3 ] [3 ]
measured in the same conditions in the presence of 10 M unlabeled ryanodine.μ
RESULTS
 presents the primary structure of MCa, the domain A and the domain C of the II-III loop of the skeletal muscle  DHPR.Figure 1A α1
Biotinylated peptides, named MCa , peptide-A  (pA ) and peptide-C  (pA ) corresponding to these different sequences wereb Sk sk Sk sk
synthesized and immobilized on polystyrene beads coated with streptavidine.  shows the SDS PAGE analysis of the bound RyR1Figure 1B
fraction following incubation of beads covered with each of the peptide with purified RyR1 as described in Materials. A polypeptide band
corresponding to RyR1 is only observed in the bound fraction obtained with beads covered with MCa , peptide-A . No signal wasb Sk
detected when beads were covered with peptide-C  or biotin. These results confirm the specificity of the interaction between the skeletalSk
sequence of domain A and RyR1 and represent the first biochemical evidence of a direct interaction of MCa with RyR1.
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In order to identify the amino acid sequences of RyR1 involved in the interaction with MCa  and peptide-A , we generated a contig ofb sk
nine clones encompassing the full length RyR1 cDNA in plasmids ( ). Each of these clones was expressed separately in an Figure 1C in
 cell-free translation system in the presence of radiolabeled S -methionine. RyR1 fragments (F1 9) were incubated in the presencevitro [35 ] –
of beads covered either with MCa , peptide-A , peptide-C  or biotin. The fragments interacting with the different peptides were thenb sk sk
detected by autoradiography after separation on SDS-PAGE.  shows that among the nine translated fragments, F7 fragmentFigure 1C
encompassing RyR1 amino acid residues 3201-3661 interacts strongly with MCa  and with peptide-A . Fragment F3 encompassing theb sk
RyR1 amino acid residues 1021-1631 consistently shows a weak interaction with both MCa  and peptide-A . In agreement with what isb sk
observed with purified RyR1, no significant interaction with peptide-C  was observed with any of the nine RyR1 fragments. Similarly, nosk
interaction was observed of any fragment with beads covered with biotin (not shown). Statistical analysis of the amount of complex
formed with each of the fragment shows that about 50  of the F7 fragment interacts with MCa  or peptide-A , while only about 15  of% b sk %
the F3 fragment was retained by MCa  or peptide-A . For all other fragments, the amount of complex formed with MCa  or peptide-Ab sk b sk
was not significantly different from what observed with peptide-C  and represented less than 5  of the input.sk %
To further define the RyR1 sequence that interacts with MCa  and peptide-A , the cDNA corresponding to F7 was subcloned intob Sk
three smaller fragments, named F7.1, F7.2 and F7.3, encompassing RyR1 amino acid residues 3201-3350, 3351-3501 and 3502-3661,
respectively ( ). Corresponding polypeptides were then expressed in E. coli, affinity-purified trough their histidine tags, andFigure 2A
tested for their interaction with MCa  and peptide-A . Interacting fragments were detected by immunolabeling with antibodies directedb sk
against the his-tag, after separation on SDS-PAGE.  shows that only the fragment F7.2, encompassing amino acid residuesFigure 2A
3351-3501, retains the ability to interact with both MCa  and peptide-A . No interaction was observed with fragment F7.1 or F7.3. Theb sk
specificity of the interaction of the F7.2 fragment with MCa  and peptide-A  was confirmed by the lack of signal with beads covered withb sk
peptide-C  or biotin (data not shown). We therefore investigated the ability of MCa  to inhibit the interaction of fragment F7.2 withsk b
peptide-A . Incubation of fragment F7.2 for 2 h in the presence of non-biotinylated MCa induces a complete loss of interaction of thissk
fragment with immobilized peptide-A  ( ) strongly suggesting that MCa and peptide-A  interact on the same site on the F7.2sk Figure 2B sk
fragment.
We next investigated the importance of the F7 region in the sensitivity of RyR1 to MCa. For this purpose, COS-7 cells were
co-transfected with two plasmids encoding the DsRed protein and the entire RyR1 (RyR1wt) or the RyR1 deleted of residues 3241-3661
(RyR1 F7) ( ). Immunolabeling of DsRed-positive cells with antibodies directed against the C-terminal domain of RyR1Δ Figure 3
demonstrates that RyR1wt and RyR1 F7 exhibit a similar cell distribution. The distribution essentially consists in a cytoplasmic labelingΔ
most likely representing the endoplasmic reticulum ( ). Fluorescence analysis showed that about 10  of cells co-express DsRedFigure 3A %
and RyRwt or DsRed and RyR F7. A weak labeling with anti-RyR1 antibodies was also observed in cells that do not express DsRedΔ
protein, suggesting that some cells could express exogenous RyR1 without DsRed or that they possess a low level of endogenous RyR1
expression (however barely detected by Western blot analysis, ).Figure 3B
In order to establish the functional relevance of the F7 region in RyR1 regulation by MCa or peptide-A , we characterized the bindingsk
of H -ryanodine on RyR1wt or RyR1 F7 expressed in COS-7 cells and tested the effects of both caffeine and MCa on this binding. For[3 ] Δ
this purpose, we prepared microsomes from cells transfected with either RyR1wt or RyR1 F7. Immunoblot analysis of the differentΔ
microsome preparations using antibodies directed against RyR1 (  upper panel) supports the localization of expressed RyR1wtFigure 3B
and RyR1 F7 in reticulum membrane of transfected cells. These results also show that RyR1wt and RyR1 F7 are expressed at a similarΔ Δ
level and remain stable in transfected cells. Finally, endogenous RyR1, if present, is barely measurable. Using these microsome
preparations, we then measured H -ryanodine binding on expressed RyR1wt and RyR1 F7 in the presence or absence of caffeine or[3 ] Δ
MCa. No significant specific H -ryanodine binding was observed on microsomes obtained from non-transfected cells ( ). In[3 ] Figure 3B
addition, no effect of caffeine or MCa was observed on these control microsomes (data not shown). This data confirmed immunological
and Western blot data showing a low level if any of endogenous RyR1 in COS-7 cells. In contrast, H -ryanodine binding was observed[3 ]
on microsomes populations obtained from COS-7 cells transfected with RyR1 constructs. Specific binding was 116  57 fmol/mg and 113 ±
 31 fmol/mg for microsomes obtained from RyR1wt and RyR1 F7 transfected cells, respectively. Taken together with the Western blot± Δ
analysis, these results indicate a similar H -ryanodine binding ability of expressed RyR1wt and RyR1 F7. Activation of H -ryanodine[3 ] Δ [3 ]
binding by caffeine and MCa is presented in . In the presence of 6 mM caffeine, we observed a 197  5  and 218  32Figure 3B ± % ± %
increase of H -ryanodine binding on RyR1wt and RyR1 F7 microsomes, respectively. In contrast, 30 nM MCa induced a 202  28[3 ] Δ ± %
increase of H -ryanodine binding on RyR1wt microsomes but no significant change of H -ryanodine binding on RyR1 F7 microsomes[3 ] [3 ] Δ
(107  3 ). These results clearly demonstrate that deletion of amino acids 3241 to 3661 of RyR1, included in fragment F7, induces a± %
complete loss of RyR1 sensitivity to MCa while it does not modify its sensitivity to caffeine.
DISCUSSION
Recently, we characterized the effect of MCa on RyR1 ( , ). MCa is a 33 amino acid toxin initially isolated from the venom of the13 14
scorpion , and subsequently produced by chemical peptide synthesis ( ). Based on sequence similarities, MCaScorpio maurus palmatus 24
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and IpTxA (another scorpion toxin interacting with RyR1) were proposed to share with the domain A of the skeletal DHPR  subunit aα1
common binding site(s) on RyR1. In this work, we identified two sequences of RyR1, fragment F3 encompassing amino acids 1021-1631
and fragment F7 comprising the residues 3201-3661, that are able to interact  with both MCa and domain A of the II-III loop of thein vitro
DHPR  subunit. Among these two sequences, fragment F7 displays the strongest interaction with MCa and peptide-A . We thenα1 sk
generated a RyR1 construct that lacks the amino acid region corresponding to fragment F7. This RyR1 construct with its internal deletion
displays an expression profile and a caffeine sensitivity that is perfectly similar to the wild-type RyR1. In contrast, deletion of the F7
region completely abolished the stimulatory effect of MCa on ryanodine binding, highlighting the critical role of this domain for MCa
regulation. A molecular dissection of fragment F7 allowed us to identify a discrete domain corresponding to amino acids 3351-3501
(fragment F7.2) responsible for the interaction of MCa and peptide-A  with RyR1. These results clearly demonstrate that, in agreementsk
with earlier expectations, MCa and domain A interact with the same RyR1 region within the 3351-3501 stretch of amino acid residues.
Binding of MCa and peptide-A  to the same RyR1 site was confirmed by the complete inhibition of the interaction of peptide-A  with thesk sk
fragment F7.2 in the presence of an excess of MCa.
Using an affinity chromatography approach, Leong and MacLennan identified a domain of RyR1 that interacts with the entire II-III
loop of the DHPR  subunit ( ). This sequence (amino acid residues 1076 to 1112) is included within our fragment F3 that we found toα1 25
interact more weakly with both peptide-A  and MCa. In contrast, these authors did not observe any significant interaction of the entire IIsk –
III loop with a polypeptide comprising amino acid residues 3158-3724 (which includes fragment F7). Our previous results, together with
those presented here, showing that domain C of  subunit does not interact with any sequence of RyR1, suggest that domain A  is theα1 sk
only sequence of II III loop interacting with RyR1 ( ). The difference between the two sets of results may reflect an effect of the distal– 21
part of the II III loop on its conformation thereby possibly modifying the accessibility of domain A  to RyR1.– sk
Several studies using either RyR1/RyR2 or RyR1/RyR3 chimeras led to the identification of different domains of RyR1 involved in
functional and structural interaction of DHPR with RyR1 ( , ). Interestingly, fragment F7 carrying the MCa and peptide-A  binding11 12 sk
domain is included in one of these domains formally defined as domain R9 or Ch-9. Similarly, the deletion of residues 1272-1455 of RyR1
(included in the F3 fragment) has been shown to induce a loss of depolarization-induced Ca release ( ). Therefore, regardless of the12
approach, the two regions of RyR1 spanning fragments F3 and F7 have been shown to play important roles in the functional
communication between RyR1 and DHPR. In agreement with previous studies suggesting that noncontiguous regions of RyR1 may act
together to control the functional coupling between RyR1 and DHPR, the F3 and F7 fragments may form a unique functional domain. This
possibility is supported by three-dimensional reconstruction of RyR1 indicating that regions including the F3 and F7 fragments could be
close from each other in the RyR1 tetramer ( ).26
In conclusion, we identified the binding domains of MCa on RyR1. We also introduce the first biochemical evidence that MCa and
domain A of the DHPR  subunit interact with identical sequences on RyR1. In view of the important effects of MCa on RyR1 gatingα1
properties ( , ), the RyR1 sequences that we identified in this report ought to play an important function in RyR1 calcium channel13 14
behavior. The fact that domain A of the II III loop of DHPR binds onto the same RyR1 sequences re-opens the question of the role of the–
domain A in the cont rol of RyR1 calcium channel activity in the context of the DHPR/RyR1 complex. Our results suggest that the two
sequences of RyR1 (F3 and F7), that are involved in the binding of MCa, could fold together to create a unique MCa binding site.
Cryoelectron microscopy studies of the RyR1-MCa complex should permit to test this hypothesis and to refine the correspondence
between primary structure and 3-D reconstruction images of RyR1.
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The abbreviations used are
 Ca 1.1v : Calcium channel, voltage-dependent 1.1
 CACNA1S: Calcium channel, voltage-dependent, L type, alpha-1s subunit
 SR: sarcoplasmic reticulum
 RyR1: ryanodine receptor
 DHPR: dihydropyridine receptor
 EC: excitation-contraction
 MCa: maurocalcine, MCa , biotinylated maurocalcineb
 IpTxA: imperatoxin A
 pA  sk : biotinylated peptide corresponding to the domain A of the II-III loop of the 1s subunit of the DHPRα
 pC  sk : biotinylated peptide corresponding to the domain C of the II-III loop of the 1s subunit of the DHPRα
 EGTA: Ethylene Glycol-bis(beta-aminoethyl-ether)-N,N,N ,N -TetraAcetate′ ′
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 HEPES: N- 2-Hydroxyethyl piperazine-N- 2-ethanesulfonic acid[ ] [ ]
 IPTG: Isopropylthio- -D-galactopyranosideβ
 PBS: Phosphate-Buffer Saline
 SDS-PAGE: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
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Figure 1
Identification of RyR1 fragments interacting with MCa and domain A
, Sequence alignment of maurocalcine (MCa), domain A (pA ) and domain C (pC ) of the II-III loop of the  subunit of the DHPR. GreyA sk sk α1
boxes indicate the location of conserved clusters of basic amino acid residues in MCa and pA  primary structures. In contrast, pC  does notsk sk
 exhibit this repeat of positively charged residues.  Physical interaction between purified RyR1 and MCa, domain A or domain C.B,
Biotinylated-MCa (MCa , at 40 M), biotinylated-domain A (pA , at 40 M) and biotinylated-domain C (pC , at 40 M), immobilized onb μ sk μ sk μ
streptavidine-coated magnetic beads, were used for pull-down experiments. In these conditions, MCa  (lane 2) and domain A (lane 5) showedb
an interaction with full-length purified RyR1, whereas no interaction was observed with domain C-coated beads (lane 4) or biotin-coated
 beads (lane 3). , , Autoradiogram of MCa  interaction with RyR1 fragments. After the generation of a set of clones spanning theC Upper panel b
full-length cDNA of RyR1 (dashed box indicates overlapping residues between fragments F8 and F9),  translated fragments of RyR1in vitro
 were assessed for their ability to interact either with 40 M of MCa , pA  or pC  immobilized on streptavidine-magnetic beads.μ b sk sk ,Lower panel
Histogram representing the percentage of binding of  translated RyR1 fragments to MCa , estimated by densitometry and expressed asin vitro b
the means  S.E.M. from at least three independent experiments.±
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Figure 2
Maurocalcine and domain A of the II-III loop of the  subunit bind onto the same site of RyR1α1
, Fine dissection of RyR1 fragments that interact with MCa and pA . , schematic representation of the RyR1-F7 sub-fragmentsA sk Upper panel
(F7.1, F7.2, F7.3) cloned into pMR78-his tag vector for bacteria expression and affinity chromatography purification. , WesternLower panel
 blot with anti-his antibodies, showing the specific pull-down of the F7.2 fragment of RyR1 with both MCa  and pA .b sk , Western blotB
resulting from a competition experiment, where the RyR1-F7.2 fragment was preincubated with an excess of MCa (1 M) and then incubatedμ
with 16 nM of pAsk previously immobilized on streptavidine-magnetic beads. While the fragment F7.2 was able to bind to pAsk  (left lane),b
the presence of MCa abolished this interaction (right lane), showing a competition of these two peptides for the same binding site on RyR1.
J Biol Chem. Author manuscript
Page /9 9
Figure 3
Deletion of the F7 region abolishes the effect of maurocalcine on H -ryanodine binding onto RyR1 expressed in COS-7 cells[3 ]
, RyR expression pattern in COS-7 cells cotransfected either with DsRed and RyR1wt (upper panels) or with DsRed and RyR1- F7 (lowerA Δ
panels) in COS-7 cells. Immunofluorescent signal in left panels (green signal) show the distribution pattern of RyR1 and red signal in central
 panels correspond to DsRed protein. Right panels correspond to merged images. , Expression of RyR1 constructs in COS-7 cells. WesternB
blot with anti-RyR1 (C-terminal) antibodies, showing a lack of endogenous RyR1 expression (lane 1) in control cells and equal protein
 amounts of RyR1 wt (lane 2) and RyR1- F7 (lane 3) in 50 g of microsomes, 48h after transfection.Δ μ , Functional effect of the F7 deletion onC
RyR1 binding properties. H -ryanodine binding experiments on purified cell microsomes showed that, while both constructs responded to[3 ]
caffeine administration (6 mM), the deletion of the F7 fragment abolished MCa effect (30 nM).
